Skip to main content
Ten scientists from the Department of Energy’s Oak Ridge National Laboratory are among the world’s most highly cited researchers. Credit: ORNL, U.S. Dept. of Energy

Ten scientists from the Department of Energy’s Oak Ridge National Laboratory are among the world’s most highly cited researchers, according to a bibliometric analysis conducted by the scientific publication analytics firm Clarivate.

Researchers studying secondary metabolites in the fungus Aspergillus flavus, pictured, found unique mixes of metabolites corresponding to genetically distinct populations. The finding suggests local environmental conditions play a key role in secondary metabolite production, influencing the discovery of drugs and other useful compounds. Credit: Tomás Allen Rush/ORNL, U.S. Dept. of Energy.

Scientists at ORNL and the University of Wisconsin–Madison have discovered that genetically distinct populations within the same species of fungi can produce unique mixes of secondary metabolites, which are organic compounds with applications in

An ORNL-led team comprising researchers from multiple DOE national laboratories is using artificial intelligence and computational screening techniques – in combination with experimental validation – to identify and design five promising drug therapy approaches to target the SARS-CoV-2 virus. Credit: Michelle Lehman/ORNL, U.S. Dept. of Energy

An ORNL-led team comprising researchers from multiple DOE national laboratories is using artificial intelligence and computational screening techniques – in combination with experimental validation – to identify and design five promising drug therapy approaches to target the SARS-CoV-2 virus.

ORNL and NASA’s Jet Propulsion Laboratory scientists studied the formation of amorphous ice like the exotic ice found in interstellar space and on Jupiter’s moon, Europa. Credit: NASA/JPL-Caltech

Researchers from NASA’s Jet Propulsion Laboratory and Oak Ridge National Laboratory successfully created amorphous ice, similar to ice in interstellar space and on icy worlds in our solar system. They documented that its disordered atomic behavior is unlike any ice on Earth.

Vittorio Badalassi, left, of Oak Ridge National Laboratory leads the Fusion Energy Reactor Models Integrator, or FERMI, project, and collaborates with ORNL computational physicist David Green. FERMI applies fission platforms to fusion reactor design. Credit: Commonwealth Fusion Systems and Colby Earles/ORNL, U.S. Dept. of Energy

Oak Ridge National Laboratory expertise in fission and fusion has come together to form a new collaboration, the Fusion Energy Reactor Models Integrator, or FERMI

ORNL’s Sergei Kalinin and Rama Vasudevan (foreground) use scanning probe microscopy to study bulk ferroelectricity and surface electrochemistry -- and generate a lot of data. Credit: Jason Richards/ORNL, U.S. Dept. of Energy

At the Department of Energy’s Oak Ridge National Laboratory, scientists use artificial intelligence, or AI, to accelerate the discovery and development of materials for energy and information technologies.

Belinda Akpa applies her diverse expertise and high-performance computing to accelerate the drug discovery process and increase the chances of success when candidate molecules go to clinical trials. Credit: Carlos Jones/ORNL, U.S. Dept. of Energy

Belinda Akpa is a chemical engineer with a talent for tackling big challenges and fostering inclusivity and diversity in the next generation of scientists.

Rich Giannone uses bioanalytical mass spectrometry to examine proteins, the primary driver in biological systems.

Rich Giannone uses bioanalytical mass spectrometry to examine proteins, the primary driver in biological systems.

ATOM logo

The Accelerating Therapeutics for Opportunities in Medicine , or ATOM, consortium today announced the U.S. Department of Energy’s Oak Ridge, Argonne and Brookhaven national laboratories are joining the consortium to further develop ATOM’s artificial intelligence, or AI-driven, drug discovery platform.

Neutron scattering experiments show electric charges, shown in red, blue and grey, in the SARS-CoV-2 main protease site where telaprevir binds to the structure. The experiments provide critical data for the design of small-molecule drugs to treat COVID-19. Credit: Jill Hemman and Michelle Lehman/ORNL, U.S. Dept. of Energy

Scientists have found new, unexpected behaviors when SARS-CoV-2 – the virus that causes COVID-19 – encounters drugs known as inhibitors, which bind to certain components of the virus and block its ability to reproduce.